Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06224543 · ClinicalTrials.gov registry record · Phase 1
MR Image Synthesis With Low Gadobutrol Dose and AI
A Phase 1 study of Enhancing Brain Lesions, sponsored by Subtle Medical.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 5
- Study locations
NCT06224543: Completed Phase 1 study of Enhancing Brain Lesions, sponsored by Subtle Medical.
NCT06224543 is a Phase 1 study of Enhancing Brain Lesions that has completed, run by Subtle Medical. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06224543, a Phase 1 study of Enhancing Brain Lesions, has completed, sponsored by Subtle Medical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
Study 22403 is a Phase 1 / Proof of Concept exploratory investigation to assess the non-inferiority of low dose gadobutrol and SubtleGAD™, a software medical device using an Artificial Intelligence (AI) deep learning-based method to enhance the contrast signal from images acquired with low dose administration of gadobutrol (GAD) contrast. The primary objective is to demonstrate noninferiority of synthesized Central Nervous System (CNS) magnetic resonance (MR) images for 1 or 2 different gadobutrol-enhanced low-dose groups (0.01mmol/kg, and0.025 mmol/kg) compared to gadobutrol-enhanced CNS MR images at a standard dose of 0.1 mmol/kg. This investigation is a prospective, randomized, open label, multi-center study with blinded reads in participants with known or highly suspected CNS pathology. There will be at least 60 participants enrolled (30 per study arm). SubtleGAD will be used as a post-processing tool, prior to blinded read assessment of MR images acquired in either arm of the study.
Primary Outcome
Compare enhancing lesions in gadobutrol-enhanced central nervous system (CNS) magnetic resonance imaging (MRI) low dose groups (0.01 mmol/kg, 0.025 mmol/kg), and standard dose (0.1 mmol/kg).
Conditions Studied
Interventions
- DRUG Gadobutrol
- DEVICE SubtleGAD
Study Locations (5)
Illinois
- Central Illinois Radiological Associates; OSF St. Francis Hospital Peoria - Peoria
Massachusetts
- UMass Chan Medical School - Worcester
Minnesota
- Mayo Clinic - Rochester
Pennsylvania
- The Pennsylvania State University - State College
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-06-16 |
| Est. Completion | 2025-08-15 |
| Phase | Phase 1 |
What the finished NCT06224543 record still lists
NCT06224543 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Enhancing Brain Lesions appearing as the primary indexed condition, and to 2 interventions - of which Gadobutrol is the first listed.
NCT06224543 lists 5 locations in 5 states (Illinois, Massachusetts, Minnesota).
Frequently Asked Questions
What is clinical trial NCT06224543 about?
NCT06224543 is a clinical study titled "MR Image Synthesis With Low Gadobutrol Dose and AI". Study 22403 is a Phase 1 / Proof of Concept exploratory investigation to assess the non-inferiority of low dose gadobutrol and SubtleGAD™, a software medical device using an Artificial Intelligence (AI) deep learning-based method to enhance the contrast signal from images acquired with low dose admi...
What is the current status of trial NCT06224543?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-06-16. Estimated completion is 2025-08-15.
What conditions does trial NCT06224543 study?
This clinical trial studies the following conditions: Enhancing Brain Lesions.
What interventions are being tested in trial NCT06224543?
The interventions under investigation include: Gadobutrol (DRUG), SubtleGAD (DEVICE).
Who is sponsoring clinical trial NCT06224543?
This trial is sponsored by Subtle Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06224543 being conducted?
This trial has 5 study locations across Illinois, Massachusetts, Minnesota, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06224543's enrollment target sits among peer trials
60 831st of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI